Lawrence F. Eichenfield

Guest Editor for the following articles:

Vol. 36. No. 3

Atopic dermatitis: skin care and topical therapies

Adam Friedman, MD | David Fleischer, MD | Jeffrey Bienstock, MD | Jenna Borok, BS | Jeremy Udkoff, MA | Lawrence F. Eichenfield, MD | Megha M Tollefson, MD | Noreen Nicol, MS, RN, FNP | Peter Lio, MD
Vol. 36. No. 2

Nonpharmacologic Strategies and Topical Agents for Treating Atopic Dermatitis: An Update

Lawrence F. Eichenfield, MD | Linda Stein Gold, MD

The signs and symptoms of atopic dermatitis can be safely and effectively controlled in most patients; in many cases, the disease can be improved to the point that signs and symptoms are absent or minimal. In addition, flares can be effectively controlled and, in some cases, prevented.

If you would like to complete the CME portion of this Supplement, please click here.

Vol. 20. No. 4

Pimecrolimus (Elidel, SDZ ASM 981)– Preclinical Pharmacologic Profile and Skin Selectivity

Anton Stuetz, PhD | Maximillian Grassberger, PhD | Josef G Meingassner, DVM

The ascomycin macrolactam derivative pimecrolimus (Elidel, SDZ ASM 981; Novartis Pharma AG, Basel Switzerland) is a cell-selective inhibitor of inflammatory cytokines specifically developed for the treatment of inflammatory skin diseases, such as atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, and plaque-type psoriasis.